Drugs, Pregnancy & Lactation

Q&A with the FDA: Implementing the Pregnancy and Lactation Labeling Rule


 

Q: Does the FDA have any plans to address labeling for over-the-counter products in terms of their impact on pregnancy, lactation, and reproductive potential?

A: The PLLR does not apply to over-the-counter products. However, the agency is continually reviewing the safety of products used over the counter, including impacts on pregnancy, lactation, and reproductive potential.

Q: How does the FDA plan to assess over time the usefulness of the new labeling for prescribers and patients and make revisions?

A: The draft guidance was issued concurrently with PLLR. Based on the comments received from the public on the draft, as well as learning from the initial revisions of labeling, the guidance will be revised as needed. Guidance statements issued by FDA are regularly reviewed and revised as needed.

Dr. Whyte, a board-certified internist, is the director of Professional Affairs and Stakeholder Engagement at the FDA. Do you have other questions about the PLLR? Send them to obnews@frontlinemedcom.com.

Pages

Recommended Reading

VIDEO: Don’t forget folate for women on antiepilepsy drugs
MDedge Internal Medicine
AMWA: Recognizing human-trafficking victims
MDedge Internal Medicine
To drink or not to drink – What do you tell your patients?
MDedge Internal Medicine
ACOG: IV regimen safely resolved acute headache in pregnant women
MDedge Internal Medicine
VIDEO: Are birthing centers a safe choice for women?
MDedge Internal Medicine
VIDEO: Cervicovaginal microbiome holds promise in preventing preterm birth
MDedge Internal Medicine
NASPAG: Migraines don’t always preclude combined OCs
MDedge Internal Medicine
PAS: Getting a grip on glucokinase MODY
MDedge Internal Medicine
DDW: Gestational diabetes linked to increased NAFLD risk in middle age
MDedge Internal Medicine
Uncomplicated pregnancies in women with lupus may not boost risk for CV events
MDedge Internal Medicine

Related Articles